<?xml version='1.0' encoding='utf-8'?>
<document id="29604332"><sentence text="Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach."><entity charOffset="11-30" id="DDI-PubMed.29604332.s1.e0" text="hydrochlorothiazide" /><entity charOffset="35-45" id="DDI-PubMed.29604332.s1.e1" text="amlodipine" /><entity charOffset="86-95" id="DDI-PubMed.29604332.s1.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.29604332.s1.e0" e2="DDI-PubMed.29604332.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s1.e0" e2="DDI-PubMed.29604332.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s1.e0" e2="DDI-PubMed.29604332.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s1.e1" e2="DDI-PubMed.29604332.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s1.e1" e2="DDI-PubMed.29604332.s1.e2" /></sentence><sentence text="Fixed dose combination (FDC) of valsartan (VAL) and hydrochlorothiazide (HCT) or VAL and amlodipine (AML) has been available in many countries for the treatment of hypertension"><entity charOffset="32-41" id="DDI-PubMed.29604332.s2.e0" text="valsartan" /><entity charOffset="43-46" id="DDI-PubMed.29604332.s2.e1" text="VAL" /><entity charOffset="52-71" id="DDI-PubMed.29604332.s2.e2" text="hydrochlorothiazide" /><entity charOffset="73-76" id="DDI-PubMed.29604332.s2.e3" text="HCT" /><entity charOffset="81-84" id="DDI-PubMed.29604332.s2.e4" text="VAL" /><entity charOffset="89-99" id="DDI-PubMed.29604332.s2.e5" text="amlodipine" /><entity charOffset="101-104" id="DDI-PubMed.29604332.s2.e6" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e0" e2="DDI-PubMed.29604332.s2.e6" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e1" e2="DDI-PubMed.29604332.s2.e6" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e2" e2="DDI-PubMed.29604332.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e2" e2="DDI-PubMed.29604332.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e2" e2="DDI-PubMed.29604332.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e2" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e2" e2="DDI-PubMed.29604332.s2.e6" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e3" e2="DDI-PubMed.29604332.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e3" e2="DDI-PubMed.29604332.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e3" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e3" e2="DDI-PubMed.29604332.s2.e6" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e4" e2="DDI-PubMed.29604332.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e4" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e4" e2="DDI-PubMed.29604332.s2.e6" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e5" e2="DDI-PubMed.29604332.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29604332.s2.e5" e2="DDI-PubMed.29604332.s2.e6" /></sentence><sentence text=" Due to drug-drug interaction potentials, in the current study we aimed to evaluate potent effects of HCT and AML on pharmacokinetics (PKs) of VAL when they are orally co-administered as FDC (VAL/HCT at 80/12"><entity charOffset="143-145" id="DDI-PubMed.29604332.s3.e0" text="VAL" /><entity charOffset="192-194" id="DDI-PubMed.29604332.s3.e1" text="VAL" /><entity charOffset="102-104" id="DDI-PubMed.29604332.s3.e2" text="HCT" /><entity charOffset="196-198" id="DDI-PubMed.29604332.s3.e3" text="HCT" /><entity charOffset="110-112" id="DDI-PubMed.29604332.s3.e4" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e2" e2="DDI-PubMed.29604332.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e2" e2="DDI-PubMed.29604332.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e2" e2="DDI-PubMed.29604332.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e2" e2="DDI-PubMed.29604332.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e2" e2="DDI-PubMed.29604332.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e4" e2="DDI-PubMed.29604332.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e4" e2="DDI-PubMed.29604332.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e4" e2="DDI-PubMed.29604332.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e4" e2="DDI-PubMed.29604332.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e0" e2="DDI-PubMed.29604332.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e0" e2="DDI-PubMed.29604332.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e0" e2="DDI-PubMed.29604332.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e1" e2="DDI-PubMed.29604332.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s3.e1" e2="DDI-PubMed.29604332.s3.e3" /></sentence><sentence text="5 mg or 160/12" /><sentence text="5 mg; and VAL/AML at 160/5 mg or 160/10 mg) products in healthy Korean subjects"><entity charOffset="10-12" id="DDI-PubMed.29604332.s5.e0" text="VAL" /><entity charOffset="14-16" id="DDI-PubMed.29604332.s5.e1" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s5.e0" e2="DDI-PubMed.29604332.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s5.e0" e2="DDI-PubMed.29604332.s5.e1" /></sentence><sentence text=" Population pharmacokinetic (PK) modeling and analysis were performed by the nonlinear mixed-effects modeling software" /><sentence text=" PKs of VAL was described by two-compartment disposition model, first-order elimination, four-sequential first-order absorption model, correlation between apparent clearances and volumes of distribution, and lag time"><entity charOffset="8-10" id="DDI-PubMed.29604332.s7.e0" text="VAL" /></sentence><sentence text=" For all FDCs, there were no statistically significant differences in both maximum concentration and areas under the concentration-time curves (AUCs) of VAL in comparison to those when administered VAL alone, except the combination of VAL/AML at 160/10 mg, where AUC0-∞ increased by 11"><entity charOffset="153-155" id="DDI-PubMed.29604332.s8.e0" text="VAL" /><entity charOffset="198-200" id="DDI-PubMed.29604332.s8.e1" text="VAL" /><entity charOffset="235-237" id="DDI-PubMed.29604332.s8.e2" text="VAL" /><entity charOffset="239-241" id="DDI-PubMed.29604332.s8.e3" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e0" e2="DDI-PubMed.29604332.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e0" e2="DDI-PubMed.29604332.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e0" e2="DDI-PubMed.29604332.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e0" e2="DDI-PubMed.29604332.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e1" e2="DDI-PubMed.29604332.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e1" e2="DDI-PubMed.29604332.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e1" e2="DDI-PubMed.29604332.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e2" e2="DDI-PubMed.29604332.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s8.e2" e2="DDI-PubMed.29604332.s8.e3" /></sentence><sentence text="8% in mean and 6" /><sentence text="86% in median" /><sentence text=" In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0"><entity charOffset="76-78" id="DDI-PubMed.29604332.s11.e0" text="VAL" /></sentence><sentence text="22-0" /><sentence text="34 h in mean and 0" /><sentence text="40-0" /><sentence text="44 h in median, except the combination of VAL/HCT at 160/12"><entity charOffset="42-44" id="DDI-PubMed.29604332.s15.e0" text="VAL" /><entity charOffset="46-48" id="DDI-PubMed.29604332.s15.e1" text="HCT" /><pair ddi="false" e1="DDI-PubMed.29604332.s15.e0" e2="DDI-PubMed.29604332.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s15.e0" e2="DDI-PubMed.29604332.s15.e1" /></sentence><sentence text="5 mg" /><sentence text=" However, these differences in AUC0-∞ and Tmax might not be considered as clinically important" /><sentence text=" In conclusion, HCT or AML has no potent effect on PKs of VAL when they are co-administered as FDC products"><entity charOffset="16-19" id="DDI-PubMed.29604332.s18.e0" text="HCT" /><entity charOffset="58-60" id="DDI-PubMed.29604332.s18.e1" text="VAL" /><entity charOffset="23-25" id="DDI-PubMed.29604332.s18.e2" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s18.e0" e2="DDI-PubMed.29604332.s18.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s18.e0" e2="DDI-PubMed.29604332.s18.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s18.e0" e2="DDI-PubMed.29604332.s18.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s18.e2" e2="DDI-PubMed.29604332.s18.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s18.e2" e2="DDI-PubMed.29604332.s18.e1" /></sentence><sentence text=" No dose adjustment for VAL is recommended when co-administered with HCT or AML"><entity charOffset="24-26" id="DDI-PubMed.29604332.s19.e0" text="VAL" /><entity charOffset="69-71" id="DDI-PubMed.29604332.s19.e1" text="HCT" /><entity charOffset="76-78" id="DDI-PubMed.29604332.s19.e2" text="AML" /><pair ddi="false" e1="DDI-PubMed.29604332.s19.e0" e2="DDI-PubMed.29604332.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29604332.s19.e0" e2="DDI-PubMed.29604332.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s19.e0" e2="DDI-PubMed.29604332.s19.e2" /><pair ddi="false" e1="DDI-PubMed.29604332.s19.e1" e2="DDI-PubMed.29604332.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29604332.s19.e1" e2="DDI-PubMed.29604332.s19.e2" /></sentence><sentence text="" /></document>